Aeluma, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Aeluma, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $4.67M | Sep 9, 2025 |
| FY2025 | Jun 30, 2024 | $919.0K | Sep 9, 2025 |
| FY2024 | Jun 30, 2023 | $193.3K | Sep 27, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($3.02M) | Sep 9, 2025 |
| FY2025 | Jun 30, 2024 | ($4.56M) | Sep 9, 2025 |
| FY2024 | Jun 30, 2023 | ($5.38M) | Sep 27, 2024 |
| FY2023 | Jun 30, 2022 | ($3.45M) | Sep 25, 2023 |
| FY2022 | Jun 30, 2021 | ($217.2K) | Sep 28, 2022 |
| FY2022 | Dec 31, 2020 | ($13.5K) | Sep 28, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($2.14M) | Sep 9, 2025 |
| FY2025 | Jun 30, 2024 | ($4.56M) | Sep 9, 2025 |
| FY2024 | Jun 30, 2023 | ($5.51M) | Sep 27, 2024 |
| FY2023 | Jun 30, 2022 | ($3.73M) | Sep 25, 2023 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $1.30M | Sep 9, 2025 |
| FY2025 | Jun 30, 2024 | $2.51M | Sep 9, 2025 |
| FY2024 | Jun 30, 2023 | $2.53M | Sep 27, 2024 |
| FY2023 | Jun 30, 2022 | $1.06M | Sep 25, 2023 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($1.15M) | Sep 9, 2025 |
| FY2025 | Jun 30, 2024 | ($3.46M) | Sep 9, 2025 |
| FY2024 | Jun 30, 2023 | ($3.64M) | Sep 27, 2024 |
| FY2023 | Jun 30, 2022 | ($2.25M) | Sep 25, 2023 |
| FY2022 | Jun 30, 2021 | ($68.4K) | Sep 28, 2022 |
| FY2022 | Dec 31, 2020 | ($1.4K) | Sep 28, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $161.0K | Sep 9, 2025 |
| FY2025 | Jun 30, 2024 | $322.0K | Sep 9, 2025 |
| FY2024 | Jun 30, 2023 | $590.0K | Sep 27, 2024 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $19.41M | Sep 9, 2025 |
| FY2025 | Jun 30, 2024 | $3.84M | Sep 9, 2025 |
| FY2024 | Jun 30, 2023 | $7.16M | Sep 27, 2024 |
| FY2023 | Jun 30, 2022 | $5.93M | Sep 25, 2023 |
| FY2022 | Jun 30, 2021 | $9.08M | Sep 28, 2022 |
| FY2022 | Dec 31, 2020 | $154.2K | Sep 28, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $1.51M | Sep 9, 2025 |
| FY2025 | Jun 30, 2024 | $1.57M | Sep 9, 2025 |
| FY2024 | Jun 30, 2023 | $1.05M | Sep 27, 2024 |
| FY2023 | Jun 30, 2022 | $831.1K | Sep 25, 2023 |
| FY2022 | Jun 30, 2021 | $897.6K | Sep 28, 2022 |
| FY2022 | Dec 31, 2020 | $147.9K | Sep 28, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $17.90M | Sep 9, 2025 |
| FY2025 | Jun 30, 2024 | $2.28M | Sep 9, 2025 |
| FY2025 | Jun 30, 2023 | $6.11M | Sep 9, 2025 |
| FY2024 | Jun 30, 2022 | $5.10M | Sep 27, 2024 |
| FY2023 | Jun 30, 2021 | $8.19M | Sep 25, 2023 |
| FY2022 | Dec 31, 2020 | $6.3K | Sep 28, 2022 |
| FY2022 | Dec 31, 2019 | ($249) | Sep 28, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($16.65M) | Sep 9, 2025 |
| FY2025 | Jun 30, 2024 | ($13.62M) | Sep 9, 2025 |
| FY2024 | Jun 30, 2023 | ($9.06M) | Sep 27, 2024 |
| FY2023 | Jun 30, 2022 | ($3.68M) | Sep 25, 2023 |
| FY2022 | Jun 30, 2021 | ($230.9K) | Sep 28, 2022 |
| FY2022 | Dec 31, 2020 | ($13.7K) | Sep 28, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $3.63M | Sep 9, 2025 |
| FY2025 | Jun 30, 2024 | $1.29M | Sep 9, 2025 |
| FY2024 | Jun 30, 2023 | $5.07M | Sep 27, 2024 |
| FY2022 | Jun 30, 2022 | $3.74M | Sep 28, 2022 |
| FY2022 | Jun 30, 2021 | $6.79M | Sep 28, 2022 |
| FY2022 | Dec 31, 2020 | $38.3K | Sep 28, 2022 |
| FY2022 | Dec 31, 2019 | $206 | Sep 28, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 0 | Sep 9, 2025 |
| FY2025 | Jun 30, 2024 | 0 | Sep 9, 2025 |
| FY2024 | Jun 30, 2023 | 0 | Sep 27, 2024 |
| FY2023 | Jun 30, 2022 | 0 | Sep 25, 2023 |
| FY2022 | Jun 30, 2021 | 0 | Sep 28, 2022 |
| FY2022 | Dec 31, 2020 | 0 | Sep 28, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 0 | Sep 9, 2025 |
| FY2025 | Jun 30, 2024 | 0 | Sep 9, 2025 |
| FY2024 | Jun 30, 2023 | 0 | Sep 27, 2024 |
| FY2023 | Jun 30, 2022 | 0 | Sep 25, 2023 |
| FY2022 | Jun 30, 2021 | 0 | Sep 28, 2022 |
| FY2022 | Dec 31, 2020 | 0 | Sep 28, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 15.86M | Sep 9, 2025 |
| FY2025 | Jun 30, 2024 | 12.18M | Sep 9, 2025 |
| FY2024 | Jun 30, 2023 | 12.82M | Sep 27, 2024 |
| FY2023 | Jun 30, 2022 | 10.65M | Sep 25, 2023 |
| FY2022 | Jun 30, 2021 | 10.54M | Sep 28, 2022 |
| FY2022 | Dec 31, 2020 | 3.25M | Sep 28, 2022 |